Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, Webster A, Nicolucci A, Zoungas S, Strippoli GF.

Ann Intern Med. 2012 Mar 20;156(6):445-59. doi: 10.7326/0003-4819-156-6-201203200-00007. Review.

PMID:
22431677
2.

Antiplatelet agents for chronic kidney disease.

Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GF.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2. Review.

PMID:
23450589
3.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
4.

Antiplatelet agents for intermittent claudication.

Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD001272. doi: 10.1002/14651858.CD001272.pub2. Review.

PMID:
22071801
5.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

6.

Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.

Lin TH, Lai WT, Hsin HT, Li AH, Wang CL, Kuo CT, Hwang JJ, Chiang FT, Chang SC; ACS Full Spectrum Registry Investigators.

PLoS One. 2013 Aug 28;8(8):e71917. doi: 10.1371/journal.pone.0071917. eCollection 2013.

7.

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO Investigators.

Am Heart J. 2008 Apr;155(4):687-93. doi: 10.1016/j.ahj.2007.10.046. Epub 2008 Feb 21.

PMID:
18371477
8.

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

Keller TT, Squizzato A, Middeldorp S.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005158. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD005158.

PMID:
17636787
9.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

10.

Updates in antiplatelet agents used in cardiovascular diseases.

Cheng JW.

J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):514-24. doi: 10.1177/1074248413499971. Review.

PMID:
24213473
11.

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.

PMID:
18319394
12.

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease.

Robey RB, O'Rourke DJ.

Ann Intern Med. 2012 Aug 21;157(4):302-3; author reply 303-4. doi: 10.7326/0003-4819-157-4-201208210-00024. No abstract available.

PMID:
22910952
13.

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease.

Kussmaul W.

Ann Intern Med. 2012 Aug 21;157(4):302; author reply 303-4. doi: 10.7326/0003-4819-157-4-201208210-00023. No abstract available.

PMID:
22910951
14.
15.

Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

Martin MT, Spinler SA, Nutescu EA.

Clin Ther. 2011 Apr;33(4):425-42. doi: 10.1016/j.clinthera.2011.04.007. Review.

PMID:
21635989
16.

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.

Valentine N, Van de Laar FA, van Driel ML.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD005449. doi: 10.1002/14651858.CD005449.pub2. Review.

PMID:
23152231
17.

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF.

Ann Intern Med. 2010 Jul 6;153(1):23-33. doi: 10.7326/0003-4819-153-1-201007060-00252. Epub 2010 Jun 24. Review.

PMID:
20439566
18.

Antiplatelet agents and anticoagulants for hypertension.

Lip GY, Felmeden DC, Dwivedi G.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003186. doi: 10.1002/14651858.CD003186.pub3. Review.

PMID:
22161375
19.

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.

Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL.

Am J Cardiovasc Drugs. 2007;7(4):289-97.

PMID:
17696569
20.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Kom├│csi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191

Supplemental Content

Support Center